类风湿关节炎继发骨质疏松症临床防治药物研究现状

Current status of research on clinical drugs for prevention and treatment of osteoporosis secondary to rheumatoid arthritis

类风湿关节炎(RA)为临床较为多见的关节炎性疾病之一,发病机制较为复杂,多发于女性群体。RA以对称性、慢性多关节炎为主要特征,伴有全身多系统受累,具有较高的致残风险,严重威胁患者身心健康。骨质疏松症(OP)是以单位体积内骨量减少、骨微结构退化、骨强度降低等为特征的系统性骨病,为RA的主要并发症之一。RA疾病进展与治疗均会对骨质结构、骨代谢造成一定影响,继发OP风险较高。RA继发OP病情复杂,治疗难度大,既往临床缺乏治疗该病的特效药物,而近些年随着新型药物研发不断深入,为RA继发OP的防治带来新的选择。为此,本文从各类药物防治RA继发OP的作用机制做一综述。

Rheumatoid arthritis(RA)is one of the most common arthritis diseases in clinic.Its pathogenesis is complex,and it often occurs in women.RA is characterized by symmetry and chronic polyarthritis,with multiple systemic involvement,which has a high risk of disability and seriously threatens the physical and mental health of patients.Osteoporosis(OP)is a systemic osteopathy characterized by bone loss per unit volume,bone microstructure degradation,and bone strength reduction,which is one of the main complications of RA.The progression and treatment of RA disease will have some impact on bone structure and bone metabolism,and the risk of secondary OP is high.The disease of RA secondary OP is complex and difficult to treat.In the past,there was no specific drug to treat the disease in clinic.In recent years,with the development of new drugs,new options have been brought for the prevention and treatment of RA secondary OP.Therefore,this article reviews the mechanism of various drugs in preventing and treating OP secondary to RA.